Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
21 déc. 2018 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
12 déc. 2018 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
27 nov. 2018 10h52 HE
|
Helsinn Healthcare S.A.
The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients LUGANO, SWITZERLAND, AND NEW YORK, NY,...